Saturday , August 18 2018
Home / Resources / Articles / Vast Array of New Diabetes-Related Medications Under Development

Vast Array of New Diabetes-Related Medications Under Development

Feb 27, 2014

Trade group announces 180 diabetes medicines currently in development….

The Pharmaceutical Research and Manufacturers of America (PhRMA) has announced that biopharmaceutical research companies are currently developing 180 new medicines aimed to help those affected by diabetes. Of these drugs in development, 128 of them are indicated for diabetes and 52 of them are indicated for diabetes-related conditions. Of the medicines that are indicated for diabetes, 30 of them are indicated for type 1 diabetes and 100 of them are for type 2 diabetes. Several examples of the new medications that are being tested include one that improves glucose-dependent insulin secretion, another that inhibits an enzyme linked to diabetic neuropathy, and a treatment that is designed to stimulate and enhance the regeneration of insulin producing cells. Other potential innovations from these new medications include medications that have a longer therapeutic life that can lead to once-weekly treatment, and a medication that may be able to treat diabetic nephropathy.

See more SGLT-2 Resources

There have been several new diabetes medications that have been approved by the FDA within the last year. These include Nesina, Invokana, Duetact, and Farxiga. Nesina is a DPP-IV inhibitor which blocks the inactivation of incretin hormones: hormones that stimulate insulin release and inhibit glucagon release which leads to the lowering of blood glucose. Invokana and Farxiga are part of a class of SGLT-2 inhibitors that allow excess glucose to be eliminated in the urine. Duetact is a combination of two already available diabetes medications, pioglitazone and glimepiride, with pioglitazone targeting insulin resistance and glimepiride increasing the amount of insulin produced by the pancreas.

By developing new treatments and medications for diabetes, these biopharmaceutical companies aim to develop more effective therapies to reduce the human toll and economic costs of diabetes.

Diabetes/Metabolism Research & Reviews 2014; Source: PhRMA 2014 Diabetes Report